A phase II study of active specific immunotherapy and 5-FU/Leucovorin as adjuvant therapy for stage III colon carcinoma

A Baars1, AME Claessen2,4, J Wagstaff1,5, G Giaccone1, RJ Scheper3, S Meijer3, MJAG Schakel2, HE Gall1, CJLM Meijer1, JB Vermorken1,6, HM Pinedo1 and AJM van den Eertwegh*,1

1Department of Medical Oncology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands; 2Department of Pathology, Vrije Universiteit Medical Center, Amsterdam, The Netherlands; 3Department of Surgery, Vrije Universiteit Medical Center, Amsterdam, The Netherlands.

Active specific immunotherapy, using vaccines with autologous tumour cells and BCG, significantly reduces the rate of tumour recurrence in stage II colon cancer patients, while no clinical benefit has yet been observed in stage III patients. Adjuvant treatment with 5-Fluorouracil/Leucovorin is now considered standard therapy for stage III colon carcinoma and results in an absolute survival benefit of approximately 10%. Yet, the 5-year overall survival rate of stage III colon cancer patients is only 40–50%. Combining chemotherapy and immunotherapy might improve prognosis for stage III patients, especially when considering that active specific immunotherapy and chemotherapy have shown synergistic effects in pre-clinical tumour models. We performed a phase II study with 56 patients, using the combination of active specific immunotherapy and chemotherapy as an adjuvant therapy in stage III colon cancer patients to assess the influence of 5-Fluorouracil/Leucovorin on anti-tumour immunity induced by autologous tumour cell vaccinations. Anti-tumour immunity was measured before and after chemotherapy by means of delayed type hypersensitivity reactions, taken 48 h after the third and the fourth vaccination. We also investigated the toxicity of this combined immuno-chemotherapy treatment. Delayed type hypersensitivity reactions before chemotherapy had a median size of 20.3 mm, while after chemotherapy delayed type hypersensitivity size was 18.4 mm (P=0.01), indicating that chemotherapy hardly affected anti-tumour immunity. The severity of ulcers at the BCG vaccination sites was comparable to previous studies. In 30% of the patients grade III or grade IV chemotherapy related toxicity was seen; this is comparable to what is normally observed after adjuvant chemotherapy alone. This study shows that the active specific immunotherapy-induced anti-tumour immune response is only minimally impaired by consecutive chemotherapy and that the combined treatment of stage III colon cancer patients with active specific immunotherapy and 5-Fluorouracil/Leucovorin does not cause unexpected toxicity.

British Journal of Cancer (2002) 86, 1230 – 1234. DOI: 10.1038/sj/bjc/6600254 www.bjcancer.com

Keywords: active specific immunotherapy (ASI); colon cancer; chemo-immunotherapy; delayed type hypersensitivity (DTH); autologous tumour cell vaccines

Colon cancer is one of the most prevalent malignancies in the industrialised world, with approximately 240 000 new cases diagnosed each year in the USA and Western Europe. When colon cancer is detected early, in stages I or II (Dukes A or B), the 5 year survival rate with surgery alone is 60–90%, depending on the depth of invasion of the tumour into the bowel wall. When the cancer has spread to the regional lymph nodes, or stage III (Dukes C), the 5 year survival rate is 25–60%. Important prognostic factors in stage III colon carcinoma include the number of positive nodes, extra-nodal growth, invasion of adjacent organs, grade of histologic differentiation and post-operative CEA level. When distant metastases are diagnosed, stage IV (Dukes D), the 5 year survival rate is less than 5% (Cohen et al, 1997).

Currently most patients with stage III colon carcinoma receive an adjuvant treatment with 5-Fluorouracil (5-FU) and Leucovorin. Several large studies have shown that this chemotherapeutic regimen reduces the relative death rate of stage III patients by 30–40% (Wolmark et al, 1993; Francini et al, 1994; Moertel et al, 1995; IMPACT investigators, 1995; O’Connell et al, 1997).

Our efforts have focused on active specific immunotherapy (ASI), that makes use of the patient’s own tumour to elicit a long-term anti-tumour immune response, as adjuvant therapy. Recently, we demonstrated in a randomised phase III study that adjuvant treatment with ASI, using autologous tumour cells and BCG, resulted in a significant reduction in the rate of recurrence in stages II and III colon cancer patients (Vermorken et al, 1999). Results were most pronounced in stage II patients, whereas in stage III colon cancer patients no clinically significant benefit was observed. The absence of a clinical effect in stage III colon cancer might be explained by the lack of statistical power of this study, as only 83 stage III patients were included. Furthermore, the residual tumour load in stage III patients is probably larger than in stage II patients, which could be relevant since it is known...
that ASI is more effective in a minimal residual disease setting (Hanna et al, 1979; Tamura et al, 1997; Baars et al, 2000).

In pre-clinical models ASI and chemotherapy were shown to have a synergistic anti-tumour effect. Apart from the capacity to directly destroy micro-metastases, ASI has been demonstrated to disrupt the characteristically compact structure of metastatic foci, enabling chemotherapy to reach deeper into the cancer tissue. In addition, chemotherapeutically killed tumour cells will disperse large amounts of intracellular antigens to an awaiting immune system. Furthermore, chemotherapy reduces the tumour burden, thereby increasing the chances of ASI subsequently eliminating the residual malignant cells (Hanna et al, 1982).

Several studies have demonstrated that the size of Delayed Type Hypersensitivity reactions (DTH) after autologous tumour cell vaccinations correlates strongly with recurrence and survival of cancer. The presence of a DTH response to tumour cells, 48 h after the vaccination regimen, is a measure of immunogenicity and reflects the adequacy of the vaccination and the general immune status of the patient. So far, DTH has been the only suitable parameter for the evaluation of anti-tumour immunity and the best early predictor of clinical efficacy of vaccination therapies (McCune et al, 1990; Harris et al, 2000; Baars et al, 2000; Clay et al, 2001).

Different strategies to test anti-tumour immunity have been investigated by other groups, often with disappointing results (Clay et al, 2001). Theoretically, peptide/MHC-tetramer staining of lymphocytes, with the purpose of detecting antigen specific cytotoxic T-lymphocytes, is the optimal method to evaluate the development of anti-cancer immunity (Altman et al, 1996). However, only a few tumour antigens have been identified for colon carcinoma, and it is still elusive which cancer antigens are most important for the development of a clinically relevant immune reaction. Moreover, studies investigating the correlation between the development of tetramer-positive CTL’s and clinical prognosis have shown contradictory results (Lee et al, 1999; Fong et al, 2001; Haanen et al, 2001). Therefore, at this moment we consider the DTH response to be the most reliable parameter for the evaluation of the development of an immunological anti-tumour response in colon cancer patients after active specific immunotherapy with autologous tumour cells.

In preparation for a large randomised trial we investigated in this study whether the combined anti-cancer treatment with chemotherapy and ASI can be safely administered in colon cancer patients and whether 5-FU/Leucovorin affects the efficacy of ASI. Endpoints were toxicity and the size of DTH to autologous tumour cell vaccinations before and after chemotherapy.

PATIENTS AND METHODS

Patients

Patients undergoing a colon resection for a histologically proven or clinically suspected adenocarcinoma of the large bowel were selected. Distant metastases were excluded by means of pre-operative chest X-rays and liver ultrasound or CT-scanning. Patients with stage III colon cancer were eligible for this clinical trial. A WHO performance status of 0 or 1 was required. Patients with rectal cancer, perforated tumours, Crohn’s disease, Ulcerative Colitis, previous malignancies, using immune suppressive medication, as well as pregnant and lactating women were excluded. Pathology reports were routinely reviewed on all patients. All patients gave written informed consent.

Vaccine preparation

Six Dutch hospitals participated in this study. Surgery was performed in the referring hospital. Immediately after surgery part of the tumour tissue not required for pathological examination was excised and transferred to the vaccine production laboratory of the Vrije Universiteit Medical Center, Amsterdam. The tumour was dissociated as previously described (Hanna et al, 1979; Peters et al, 1979). After this procedure viability was tested using trypan blue. Cells were aliquotted (15–20 x 10⁶ viable cells per vial) and cryopreserved using a linear freezer. Vials were stored in liquid nitrogen until vaccination. For each patient four vaccines were produced.

Vaccination procedure

Vaccination started 4–5 weeks after surgery to minimise the possible immune suppressive influence of surgery and anaesthesia. On the day of vaccination, after thawing, cells were counted and viability was assessed. For every vaccine 10⁷ viable autologous tumour cells were irradiated (200 Gy) and to the first two vaccines 10⁷ viable fresh-frozen BCG organisms were added. Vaccines were administered intra-cutaneously near sites of regional lymph nodes. The first two vaccines, containing BCG, were injected on the right and left anterior thigh respectively, at an interval of 1 week (Figure 1). In the following week the third vaccine was given in the right upper arm. Eight months after the third vaccination, and at least 4 weeks after the last cycle of chemotherapy, a booster vaccination was administered in the left upper arm.

Chemotherapy

Two weeks after the third vaccination, i.e. about 9 weeks after surgery, the first cycle of chemotherapy was given. Chemotherapy was administered in the referring hospital and normally consisted of 5-FU 425 mg m⁻² and Leucovorin 20 mg m⁻² as a bolus injection for 5 consecutive days, every 4 weeks for six cycles. In one of the participating hospitals, treating 12 of the patients described here, the chemotherapy was given in a 1 day per week schedule for 6 months, using 5-FU 600 mg m⁻² and Leucovorin 20 mg m⁻². Patient charts were audited for all patients. Toxicity of the chemotherapy was measured using the National Cancer Institute Common Toxicity Criteria for Cancer Clinical Trials, version 2.0.

DTH assessment

Response to the vaccines not containing BCG was measured by the size of induration 48 h after injection. Induration was assessed by the pen method (Sokal, 1975). For measurement of induration a line was drawn with a pen from 1 to 2 cm away from the margin of the skin test reaction towards the lesion. The pen is held at a 45° angle and moderate pressure is applied. The pen is advanced until resistance is met, indicating the edge of the area of induration. This procedure is performed in four directions. In this study the average of the two perpendicular diameters was used as the size of induration.

Figure 1 The treatment schedule that was used in this trial, showing that chemotherapy was preceded by 3 weekly tumour cell vaccinations. One month after the last gift of 5-FU a booster vaccination was administered.
Statistical analysis

Wilcoxon’s matched pairs test was used for analysing differences between DTH-values. Calculations were made with SPSS 9.0 software.

RESULTS

Patients

Between March 1996 and December 1999 colon tumours of 104 stage III patients were processed. For 78 (75%) patients adequate vaccines could be produced. Fifty-six patients received the autologous vaccines of which 53 had finished their immunisation procedure at follow-up in June 2000. Reasons for not receiving vaccination therapy although having a stage III tumour were refusal of the patient to participate in this clinical trial ($n=11$), postoperative complications ($n=4$), the use of corticosteroid medication ($n=2$), alcoholic liver insufficiency ($n=1$), ulcerative colitis ($n=1$) and advanced age ($n=3$).

The median follow-up time was 21.7 months. Patient characteristics of all vaccinated stage III patients are shown in Table 1.

Vaccine quality

The median weight of tumour received by our laboratory was 6.45 g (range 1.61–19.47 g). The median yield of tumour cells per gram of tissue was $17.9 \times 10^6$ (range $4.0–39.7 \times 10^6$).

Side effects

In all patients ulcers developed at the site of the first and second vaccination, normally after a period of 2–3 weeks. Size of these ulcers ranged from 1 to 3 cm in diameter. All ulcers healed spontaneously after a median time of 2.6 months (range 0.8–7.1 months). Twenty-two patients (39%) noticed a fever and flu-like symptoms within 48 h after vaccination and eight patients (14%) mentioned tender regional lymph nodes during several days following the vaccinations. In Table 2 the toxicity occurring during chemotherapy treatment is presented. Seventeen patients (30%) experienced grade III or grade IV toxicity. A dose reduction was required in 20 patients (36%), of which eight (14%) could not finish all scheduled cycles due to toxicity.

One patient, a 60-year old male, developed grade IV mucositis and a paralytic ileus after the first cycle of chemotherapy. Colonoscopy showed diffuse ischaemia and ulcers, while the surgical anastomosis was intact. Shortly thereafter, a multiple organ failure syndrome developed and the patient died. Seven blood cultures showed no bacterial growth. Autopsy was not performed. Death of this patient is considered to result from toxicity of 5-FU.

Delayed type hypersensitivity reaction (DTH)

In each patient some form of local reaction was seen, 48 h after the third and fourth vaccinations. This consisted of erythema and induration. As shown in Figure 2, the mean diameter of the induration after the third vaccination was 20.3 mm (s.d. 6.4). After the fourth vaccination this was 18.4 mm (s.d. 10.9). These values showed a statistically significant difference ($P=0.01$). In one patient ulceration occurred after the third vaccination, healing spontaneously within 3 weeks. The same was observed in another patient after the fourth vaccination.

DISCUSSION

This is the first study using the combined treatment of chemotherapy and autologous tumour cell vaccinations for the adjuvant treatment of colon cancer. The most important result presented here is that the DTH-reaction after the fourth autologous tumour cell vaccination is still strong, despite the fact that 5-FU/Leucovorin

Table 1 Patient characteristics

| Vaccinated stage III patients ($n=56$) |
|---------------------------------------|
| Median age at start of ASI treatment (range) | 64.3 years (25.5–78.8) |
| Sex                                    |
| Male                                   | 26 (46%) |
| Female                                 | 30 (54%) |
| Location of primary tumour             |
| Right colon                            | 18 (33%) |
| Left colon                             | 38 (67%) |
| Depth of invasion                      |
| T1                                     | 0 |
| T2                                     | 6 (10%) |
| T3                                     | 43 (80%) |
| T4                                     | 7 (10%) |
| Stage of differentiation               |
| Well                                   | 12 (21%) |
| Moderate                               | 33 (59%) |
| Poor                                   | 11 (20%) |
| Number of positive lymph nodes         |
| 0                                      | 1 (2%) |
| 1–3                                    | 35 (62%) |
| 4–7                                    | 15 (23%) |
| ≥8                                     | 5 (9%) |
| Extra-nodal growth                     | 24 (43%) |

Table 2 Moderate and severe toxicity in vaccinated stage III patients ($n=56$)

| Toxicity        | Grade II (%) | Grade III (%) | Grade IV (%) |
|-----------------|--------------|---------------|--------------|
| Diarrhoea       | 3 (5)        | 5 (9)         | 3 (5)        |
| Nausea          | 6 (11)       | 1 (2)         | 0            |
| Vomiting        | 4 (7)        | 1 (2)         | 0            |
| Ileus           | 0            | 0             | 2 (4)        |
| Mucositis       | 5 (9)        | 4 (7)         | 1 (2)        |
| Febrile neutropenia | 0        | 2 (4)         | 0            |
| Deep vein thrombosis | 0        | 1 (2)         | 0            |
| Conjunctivitis  | 1 (2)        | 0             | 0            |
| Skin rash       | 1 (2)        | 0             | 0            |

Figure 2 The diameter of the Delayed Type Hypersensitivity Reactions after the third and the fourth autologous tumour cell vaccination, measured 48 h after injection.
was administered between the third and the fourth vaccination. This is important because DTH-reactions indicate the development of specific cellular immunity and correlate strongly with survival (McCarty MC et al, 1990; Baars et al, 2000; Harris et al, 2000). A recently published study with autologous colon tumour vaccines has shown that DTH-reactions with a diameter exceeding 10 mm should be considered to reflect successful vaccination therapy and predict relatively good survival rates (Harris et al, 2000).

Thus, the chemotherapy regimen used in our protocol seems not to have a clinically important suppressive influence on the anti-tumour immunity induced by vaccination with tumour cells. However, other types of chemotherapy might have a more pronounced negative effect on anti-tumor immunity than 5-FU, so future combinations of immune therapy and chemotherapy will have to be carefully tested too, before being applied on large scale in a clinical setting.

Toxicity after the tumour cell vaccinations, consisting of ulcers after the first two injections and low grade fever in a minority of patients, was comparable to what we observed in our previous study, when no chemotherapy was used (Vermorken et al, 1999).

Side effects of the chemotherapy regimen were considerable, with grade III or grade IV toxicity occurring in 30% of patients. Gastrointestinal toxicity and mucositis were most prominent. One patient died shortly after receiving the first course of chemotherapy. Clinically, the most likely cause of death in this patient was acute mesenteric ischaemia, but this was not proven since an autopsy was not performed. Vascular toxicity is a known side-effect of 5-FU/Leucovorin, most often presenting like coronary vasospasms, but solitary bowel ischaemia has also been described (Fata et al, 1999). The precise mechanisms behind these circulatory changes are unknown (Robben et al, 1993). Overall, in this study the toxicity seen after chemotherapy was not different from the toxicity of previous studies using 5-FU/Leucovorin, and thus appears not to be influenced by the immunotherapy given in our clinical trial.

In conclusion, this study shows that the ASI-induced anti-tumour immune response is only minimally impaired by consecutive 5-FU/Leucovorin and that the combined treatment of stage III colon cancer patients with ASI and chemotherapy does not cause unexpected toxicity. Therefore, we recently started a randomised international phase III study investigating the efficacy of ASI combined with 5-FU+Leucovorin as an adjuvant treatment for stage III colon cancer patients.

ACKNOWLEDGEMENTS

This study was financially supported by INTRACEL Corporation, Frederick, Maryland 21701, USA. We are grateful to the patients who participated in this study. We also thank WM Pieterse and AN Snel for vaccine preparation. We thank MG Hanna Jr for helpful advice. We thank I Zegers for assisting with patient care. We thank H van Tinteren for assistance with statistical analyses. This study was a multi-cancer trial. Additional investigators include: JC Heijnen, JCM van der Peet, BW Schiff, H Steffelaar and JJ Verhaegh, Twente Hospital Almelo; WH Bouma and JM Smit, Hospital Center Apeldoorn; WWJ Claris, HI de Jong, WW Meijer, RJ Timmerman and HD Tjeenk Willink, Gemini Hospital Den Helder; AN Berkhoudt, FNR van Berkum, H Dankbaar, BA van Driel, CJH Gerrits, HJ Heijmans, TG Tan and BD Verhoog, Regional Hospital Midden Twente Hengelo; JWM Bol, JAC Brakenhoff, ThAA van den Broek, FX Kang le Boen and GA Vos, Waterland Hospital Purmerend; A van Bochove, AF Engel, KG van der Hem, RJLF Loftfeld, B Mak, W Mulder, JLT Oomen and RP Stratting, De Heel Zaandam.

REFERENCES

Altman JD, Moss PA, Goulder PJ, Barouch D, McHeyzer-Williams MG, Bell JJ, McMichael AJ, Davis MM (1996) Phenotypic analysis of antigen-specific T lymphocytes. Science 274: 94 – 96

Baars A, Claessen AM, van den Eertwegh AJ, Gall HE, Stam AG, Meijer S, Giaaccone G, Meijer CJ, Scheper RJ, Wagstaff J, Vermorken JB, Pinedo HM (2000) Skin tests predict survival after autologous tumour cell vaccination in metastatic melanoma: experience in 81 patients. Ann Oncol 11: 965 – 970

Clay TM, Hobelka AC, Mosca PJ, Lyerly HK, Morse MA (2001) Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin Cancer Res 7: 1127 – 1135

Cohen AM, Minsky AD, Schilsky RL (1997) Cancer of the colon. In Cancer: Principles and Practice of Oncology (5th Ed) DeVita Jr VT, Hellman S, Rosenberg SA (eds) pp 1144 – 1197, Philadelphia/New York; Lippincott–Raven

Fata F, Ron IG, Kemeny N, O’Reilly E, Klimstra D, Kelsen DP (1999) 5-Fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. Cancer 86: 1129 – 1134

Fong L, Hou Y, Benike C, Yuen A, Fisher GA, Davis MM, Engleman EG (2001) Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumour immunotherapy. FNAS 98: 8809 – 8814

Francini G, Petrioli R, Lorenzini L, Mancini S, Armenio S, Tanzini G, Marsili S, Aquino A, Mazzocca G, Civitelli S (1994) Folinic acid and 5-Fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 106: 899 – 906

Haanen JB, van Oijen M, Elias S, de Gast B, Gallee M, Schumacher T (2001) Melanoma-Specific CD8+ T-lymphocytes correlate with progressive disease in advanced-stage melanoma patients. Proc Am Soc Med Oncol 20: 1398 (abstract)

Hanna Jr MG, Bodhrost JS, Peters LC (1979) Active specific immunotherapy of residual micrometastases: an evaluation of sources, doses and ratios of BCG with tumour cells. Cancer Immunol Immunother 7: 165 – 171

Hanna Jr MG, Key ME (1982) Immunotherapy of metastases enhances subsequent chemotherapy. Science 217: 367 – 369

Harris JE, Ryan L, Hoover Jr HC, Stuart RK, Oken MM, Benson III AB, Mansour E, Haller DG, Manola J, Hanna Jr MG (2000) Adjuvant active specific immunotherapy for stage II and stage III colon cancer with autologous tumour cell vaccine: Eastern Cooperative Oncology group study E5283. J Clin Oncol 18: 148 – 157

IMPACT investigators (1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Cancer 85: 939 – 944

Lee KH, Wang E, Nielsen MB, Wunderlich J, Miguels S, Connors M, Steinberg SM, Rosenberg SA, Marincola FM (1999) Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 161: 6292 – 6300

McCune CS, O’Donnell DW, Marquis DM, Sahasrabudhe DM (1990) Renal cell carcinoma treated by vaccines for active specific immunotherapy: correlation of survival with skin testing by autologous tumour cells. Cancer Immunol Immunother 32: 62 – 66

Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangel CM, Ungerleider JS, Emerson WA, Torney DC, Glick JH, Veeder MH, Mailliard JA (1995) Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122: 321 – 326

O’Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, Widscheider HS (1997) Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15: 246 – 250

Peters LC, Hanna Jr MG (1979) Preparation of immunotherapeutic autologous vaccines from solid tumours. Cancer Res 39: 1353 – 1360

Robben NC, Pippas AW, Moore JO (1993) The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. Cancer 71: 493 – 509

Sokal JE (1975) Measurement of delayed skin test responses. Nul J Med 10: 501 – 502
Tamura Y, Peng P, Liu K, Daou M, Srivastava PK (1997) Immunotherapy of tumours with autologous tumour-derived heat shock protein preparations. 
*Science* **278**: 117–120

Vermorken JB, Claessen AME, van Tinteren H, Gall HE, Ezinga R, Meijer S, Scheper RJ, Meijer CJ, Bloemena E, Ransom JH, Hanna Jr MG, Pinedo HM (1999) Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. 
*Lancet* **353**: 345–350

Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, Jones J, Mamounas EP, Ore L, Petrelli NJ (1993) The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from the national surgical adjuvant breast and bowel project protocol C-03. 
*J Clin Oncol* **11**: 1879–1887